Sanofi-Aventis is an international pharmaceutical company.
Dr Steinmeyer’s team (Frankfurt) is specialised in the development of new cardiovascular therapeutic compounds. Among other activities, they provide the EUTRAF researchers with patented compounds to block selectively certain ion channels or transporters.
Contact: Dr. Klaus
Dr. Klaus Steinmeyer is a biologist and received his PhD for his work on cellular tumor oncogenes which he performed in the department of biochemistry at the University of Ulm and in the department of tumor virology at the Heinrich-Pette-Institute in Hamburg. As postdoctoral fellow and later as a research associate at the Center for Molecular Neurobiology Hamburg his research focused on the molecular biology of chloride channels and their role in human diseases. His academic research studies were supported by fellowships from the German National Academic Foundation and the German Research Foundation (DFG), and by grants from the DFG. He was awarded with the Heinz Maier-Leibnitz Prize of the Federal Ministry of Education and Research and obtained his Habilitation in cell biochemistry from the University of Hamburg.
He currently is head of laboratory at Sanofi where he was working for several years in the field of cardiovascular diseases, in particular of cardiac arrhythmias. His team was using molecular biological, cell biological and electrophysiological methods for the identification and validation of new targets for the treatment of atrial fibrillation and heart failure. The focus of these studies was on potassium channels responsible for the early repolarization of the cardiac action potential and also on ionic transporters involved in the intracellular calcium handling of cardiomyocytes. They were also developing cellular assays for the discovery and functional activity testing of therapeutic compounds using fluorescence-based techniques and automated patch-clamping.
Within EUTRAF Sanofi acts as exploitation manager and is involved in the research activities of work package 2. Sanofi will also provide the EUTRAF researchers with patented compounds to block selectively certain ion channels or transporters.